PE20030285A1 - Vacunacion en dosis unica con mycoplasma hyopneumoniae - Google Patents

Vacunacion en dosis unica con mycoplasma hyopneumoniae

Info

Publication number
PE20030285A1
PE20030285A1 PE2002000593A PE2002000593A PE20030285A1 PE 20030285 A1 PE20030285 A1 PE 20030285A1 PE 2002000593 A PE2002000593 A PE 2002000593A PE 2002000593 A PE2002000593 A PE 2002000593A PE 20030285 A1 PE20030285 A1 PE 20030285A1
Authority
PE
Peru
Prior art keywords
mycoplasma hyopneumoniae
pmaplco
polypeptides
units
hyopneumoniae
Prior art date
Application number
PE2002000593A
Other languages
English (en)
Spanish (es)
Inventor
Keich Robin Lee Lee
Lisa Grace Sabbadini
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23168589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20030285(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20030285A1 publication Critical patent/PE20030285A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/87—Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PE2002000593A 2001-07-02 2002-07-01 Vacunacion en dosis unica con mycoplasma hyopneumoniae PE20030285A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30263601P 2001-07-02 2001-07-02

Publications (1)

Publication Number Publication Date
PE20030285A1 true PE20030285A1 (es) 2003-03-27

Family

ID=23168589

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000593A PE20030285A1 (es) 2001-07-02 2002-07-01 Vacunacion en dosis unica con mycoplasma hyopneumoniae

Country Status (42)

Country Link
US (3) US6846477B2 (enExample)
EP (3) EP2027873B8 (enExample)
JP (1) JP2005515162A (enExample)
KR (1) KR20040030785A (enExample)
CN (3) CN102872456B (enExample)
AP (1) AP2003002937A0 (enExample)
AR (1) AR034678A1 (enExample)
AT (1) ATE412426T2 (enExample)
AU (1) AU2002309109B2 (enExample)
BG (1) BG66481B1 (enExample)
BR (1) BR0210804A (enExample)
CA (1) CA2451626C (enExample)
CY (1) CY1108749T1 (enExample)
CZ (1) CZ305781B6 (enExample)
DE (1) DE60229666D1 (enExample)
DK (3) DK2842569T3 (enExample)
DO (1) DOP2002000431A (enExample)
EA (1) EA009901B1 (enExample)
ES (3) ES2312580T5 (enExample)
GT (1) GT200200138A (enExample)
HK (1) HK1207584A1 (enExample)
HR (1) HRP20031079A2 (enExample)
HU (1) HU230246B1 (enExample)
IL (1) IL159349A0 (enExample)
IS (1) IS7076A (enExample)
MA (1) MA27047A1 (enExample)
MX (1) MXPA03011599A (enExample)
NO (1) NO342654B1 (enExample)
NZ (1) NZ530106A (enExample)
OA (1) OA12638A (enExample)
PA (1) PA8549701A1 (enExample)
PE (1) PE20030285A1 (enExample)
PL (1) PL209773B1 (enExample)
PT (3) PT2027873E (enExample)
SK (1) SK288010B6 (enExample)
TN (1) TNSN03155A1 (enExample)
TW (1) TWI329514B (enExample)
UA (1) UA78707C2 (enExample)
UY (1) UY27366A1 (enExample)
WO (1) WO2003003941A2 (enExample)
YU (1) YU102203A (enExample)
ZA (1) ZA200309698B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
WO2006056841A1 (en) * 2004-11-24 2006-06-01 Pharmacia & Upjohn Company Llc Multiple-strain mycoplasma hyopneumoniae vaccines
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
RU2488407C2 (ru) 2005-12-29 2013-07-27 Берингер Ингельхайм Ветмедика, Инк. Поливалентные иммуногенные композиции pcv2 и способы получения таких композиций
DK2371383T3 (en) 2005-12-29 2015-11-30 Boehringer Ingelheim Vetmed Use of a PCV2 immunogenic composition for reduction of clinical symptoms in pigs
AU2007222016A1 (en) * 2006-03-03 2007-09-13 Merial Limited Mycoplasma hyopneumoniae vaccine
EP2099927A4 (en) * 2006-11-22 2010-05-05 Boehringer Ingelheim Vetmed Methods of reducing porcine circovirus-associated disease outbreaks
US20100129397A1 (en) 2006-12-11 2010-05-27 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
DK2481420T3 (da) 2006-12-15 2019-05-06 Boehringer Ingelheim Animal Health Usa Inc Enkeltdosis-anti-PCV2-svinevaccine
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
AU2008324780A1 (en) 2007-11-06 2009-05-14 Pah W Llc Mycoplasma hyopneumoniae avirulent -adjuvanted live vaccine
AU2008347235A1 (en) * 2007-12-31 2009-07-16 Boehringer Ingelheim Vetmedica, Inc. PCV2 ORF2 virus like particle with foreign amino acid insertion
CN101236206B (zh) * 2008-01-17 2014-10-15 中国兽医药品监察所 一种猪肺炎支原体重组抗原elisa检测试剂盒
EP2242511A4 (en) * 2008-01-23 2012-10-24 Boehringer Ingelheim Vetmed IMMUNOGENIC COMPOSITIONS OF MYCOPLASMA HYOPNEUMONIAE PCV2, AND METHODS FOR PRODUCING SUCH COMPOSITIONS
US8444989B1 (en) * 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
NZ621834A (en) 2008-06-27 2015-10-30 Zoetis Services Llc Novel adjuvant compositions
AU2010255182B2 (en) 2009-06-04 2016-03-10 Japan Institute For Health Security Vaccine for mycoplasma infection
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
WO2011141443A1 (en) 2010-05-11 2011-11-17 Intervet International B.V. Vaccine against mycoplasma hyopneumoniae, suitable for administration in the presence of maternally derived antibodies
PL2598165T3 (pl) * 2010-07-26 2018-02-28 Qu Biologics Inc. Immunogenne kompozycje przeciwzapalne
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
BR112013004594B1 (pt) * 2010-08-27 2020-07-28 Intervet International B. V. método para a determinação de um conteúdo de antígeno
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
CA2866199A1 (en) * 2012-03-07 2013-09-12 Ceva Sante Animale Novel veterinary vaccine
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
EP3730148A3 (en) 2012-12-28 2021-03-24 Boehringer Ingelheim Vetmedica GmbH Immunogenic composition comprising mycoplasma antigens
MX361273B (es) 2012-12-28 2018-12-03 Boehringer Ingelheim Vetmedica Gmbh Metodo para obtener una vacuna de mycoplasma.
KR101758778B1 (ko) * 2013-02-05 2017-07-18 애그리컬쳐럴 테크놀로지 리서치 인스티튜트 항-마이코플라즈마 에스피피. 아단위 백신
CN104338125A (zh) * 2013-07-29 2015-02-11 普莱柯生物工程股份有限公司 一种猪肺炎支原体抗原在预防和治疗猪呼吸道疾病综合征方面的应用
NZ757210A (en) 2013-09-19 2022-12-23 Zoetis Services Llc Oil-based adjuvants
CN105658660A (zh) 2013-10-02 2016-06-08 勃林格殷格翰动物保健公司 Pcv2 orf2蛋白变体和由其组成的病毒样颗粒
CN105792841B (zh) 2013-11-21 2019-07-26 财团法人农业科技研究院 防治霉浆菌感染的组合物
CN105012948B (zh) * 2014-04-18 2019-07-30 普莱柯生物工程股份有限公司 一种疫苗组合物及其应用
CN104248753B (zh) * 2014-05-15 2017-07-28 普莱柯生物工程股份有限公司 一种疫苗组合物及其应用
BR102014014727B1 (pt) * 2014-06-16 2018-04-03 Ouro Fino Saúde Animal Ltda COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, GENE SINTÉTICO CODIFICANTE DO COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, COMPOSIÇÃO ANTIGÊNICA, PROCESSO DE OBTENÇÃO DE UM COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae
US9814769B2 (en) 2014-09-30 2017-11-14 Qatar University Vaccines against pathogenic Escherichia coli and methods of using the same
AR103427A1 (es) 2015-01-16 2017-05-10 Zoetis Services Llc Vacuna contra la fiebre aftosa
KR20160099223A (ko) * 2015-02-12 2016-08-22 강원대학교산학협력단 마이코플라스마 하이오뉴모니애 박테린 백신 및 이의 제조방법
EP3498847A4 (en) * 2016-08-12 2020-03-04 Innovac VACCINE COMPOSITION FOR PREVENTING SWINE MYCOPLASM INFECTION COMPRISING A RECOMBINANT PROTEIN
RU2668799C1 (ru) * 2017-09-08 2018-10-02 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp.
CN108101969A (zh) * 2017-11-13 2018-06-01 南京大爻网络科技有限公司 一种与猪支原体肺炎相关的抗原及其应用
RU2695679C1 (ru) * 2018-09-11 2019-07-25 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp.
RU2759427C2 (ru) * 2019-07-08 2021-11-12 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp
CN117305192A (zh) * 2023-12-01 2023-12-29 北京瑞阳瑞泰生物科技有限公司 一种猪肺炎支原体rt02株、疫苗组合物及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252328A (en) * 1987-03-26 1993-10-12 Martin Marietta Energy Systems, Inc. Mycoplasma hyopneumoniae antigen and uses therefor
EP0283840A3 (en) * 1987-03-26 1989-08-09 Ml Technology Ventures, L.P. Mycoplasma hyopneumoniae antigen and uses therefor
ES2058237T3 (es) 1987-09-18 1994-11-01 Akzo Nv Metodo para la preparacion de una vacuna para combatir la infeccion mycoplasmica en aves de corral.
JPH05506984A (ja) 1990-04-02 1993-10-14 サイナーゲン，インコーポレーテッド 動物におけるマイコプラズマ感染に対する診断と治療に有用なポリペプチド
WO1994007531A1 (en) * 1992-09-28 1994-04-14 Pfizer Inc Method of enhancing cell mediated immune responses
JP3187419B2 (ja) * 1990-05-29 2001-07-11 アメリカン・サイアナミド・カンパニー ブタ肺炎ワクチンおよびその製造方法
US6113916A (en) * 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
EP0475185A1 (en) 1990-08-27 1992-03-18 Nippon Flour Mills Co., Ltd. DNA's encoding surface antigen of mycoplasma hyopneumoniae, DNA fragments for primer, recombinant antigenic peptides and diagnostic method of mycoplasmal pneumoniae of swine using same
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5530874A (en) 1993-02-02 1996-06-25 3Com Corporation Network adapter with an indication signal mask and an interrupt signal mask
WO1995009870A1 (en) 1993-10-07 1995-04-13 Iowa State University Research Foundation, Inc. Characterization of mycoplasma hyopneumoniae adhesins
CN1268393C (zh) 1994-05-10 2006-08-09 惠氏公司 经改良修饰的brsv或疫苗
US5788962A (en) 1995-01-17 1998-08-04 The Curators Of The University Of Missouri DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures
AUPN178995A0 (en) * 1995-03-16 1995-04-13 University Of Melbourne, The Antigen composition
AU715555B2 (en) 1996-09-30 2000-02-03 University Of Arkansas, The Method of producing active immunity with vaccine conjugate
EP0846468B1 (en) 1996-12-05 2004-06-09 Akzo Nobel N.V. Non-virulent mycoplasma synoviae and vaccine thereof
BR9815321A (pt) 1997-11-26 2002-01-02 Univ Iowa State Res Found Inc Vacina de mycoplasma hyopneumoniae recombinante
AU6128900A (en) * 1999-09-29 2001-04-05 Pfizer Products Inc. Nucleic acids and proteins of the mycoplasma hyopneumoniae mph3 gene and uses thereof
US6585981B1 (en) * 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs

Also Published As

Publication number Publication date
EP1474067A2 (en) 2004-11-10
EP1474067B1 (en) 2008-10-29
ES2550458T3 (es) 2015-11-10
CN101524532A (zh) 2009-09-09
OA12638A (en) 2006-06-15
BG108546A (bg) 2005-02-28
EP2842569B1 (en) 2019-04-10
US20030109473A1 (en) 2003-06-12
IS7076A (is) 2003-12-15
EA009901B1 (ru) 2008-04-28
ATE412426T2 (de) 2008-11-15
CY1108749T1 (el) 2014-04-09
NZ530106A (en) 2007-06-29
DK1474067T4 (en) 2017-10-16
BG66481B1 (bg) 2015-02-27
CA2451626A1 (en) 2003-01-16
AR034678A1 (es) 2004-03-03
PL209773B1 (pl) 2011-10-31
GT200200138A (es) 2003-05-15
EP1474067A4 (en) 2005-08-10
PA8549701A1 (es) 2003-01-24
SK288010B6 (sk) 2012-10-02
ES2312580T3 (es) 2009-03-01
HK1134900A1 (zh) 2010-05-20
WO2003003941A2 (en) 2003-01-16
AP2003002937A0 (en) 2003-12-31
US20050013823A1 (en) 2005-01-20
PT1474067E (pt) 2008-11-14
NO20035762L (no) 2004-02-02
ES2729579T3 (es) 2019-11-04
CN1551781A (zh) 2004-12-01
EP2027873B8 (en) 2015-11-11
PL373367A1 (en) 2005-08-22
HK1207584A1 (en) 2016-02-05
EA200301323A1 (ru) 2005-06-30
NO342654B1 (no) 2018-06-25
MXPA03011599A (es) 2005-03-07
USRE44399E1 (en) 2013-07-30
EP1474067B2 (en) 2017-08-16
UY27366A1 (es) 2003-04-30
YU102203A (sh) 2006-05-25
KR20040030785A (ko) 2004-04-09
CZ20033466A3 (cs) 2005-06-15
DK1474067T3 (da) 2008-12-08
HK1068250A1 (en) 2005-04-29
CN101524532B (zh) 2014-03-19
CZ305781B6 (cs) 2016-03-16
PT2027873E (pt) 2015-11-03
PT2842569T (pt) 2019-06-17
TWI329514B (en) 2010-09-01
DK2027873T3 (en) 2015-11-09
BR0210804A (pt) 2005-05-03
CN102872456B (zh) 2016-01-20
DK2842569T3 (da) 2019-05-20
DOP2002000431A (es) 2003-01-15
WO2003003941A3 (en) 2004-07-29
US6846477B2 (en) 2005-01-25
HU230246B1 (hu) 2015-11-30
CN102872456A (zh) 2013-01-16
JP2005515162A (ja) 2005-05-26
ES2312580T5 (es) 2017-12-11
EP2027873B1 (en) 2015-09-09
CN1551781B (zh) 2013-01-02
EP2027873A1 (en) 2009-02-25
HRP20031079A2 (en) 2005-10-31
IL159349A0 (en) 2004-06-01
DE60229666D1 (de) 2008-12-11
EP2842569A1 (en) 2015-03-04
ZA200309698B (en) 2014-04-30
HUP0400434A2 (en) 2007-08-28
SK15792003A3 (sk) 2005-09-08
TNSN03155A1 (fr) 2005-12-23
AU2002309109B2 (en) 2007-12-13
HK1180224A1 (zh) 2013-10-18
MA27047A1 (fr) 2004-12-20
UA78707C2 (en) 2007-04-25
CA2451626C (en) 2011-05-31

Similar Documents

Publication Publication Date Title
PE20030285A1 (es) Vacunacion en dosis unica con mycoplasma hyopneumoniae
Dhama et al. DNA vaccines and their applications in veterinary practice: current perspectives
Hiszczyńska-Sawicka et al. Evaluation of immune responses in sheep induced by DNA immunization with genes encoding GRA1, GRA4, GRA6 and GRA7 antigens of Toxoplasma gondii
AR014182A1 (es) Composiciones de vacunas utiles para el tratamiento o profilaxis de tumores o lesiones inducidas por hpv; procedimiento para prevenir o tratar tumoresinducidos por hpv y procedimiento para preparar dichas composiciones
Park et al. Enhanced immune responses of foot-and-mouth disease vaccine using new oil/gel adjuvant mixtures in pigs and goats
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
PE20030239A1 (es) Vacuna de mycoplasma bovis y metodos para reducir la neumonia en animales
JP2005515162A5 (enExample)
ES2149361T3 (es) Vacuna viva modificada contra el brsv, mejorada.
BRPI0816134A2 (pt) Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença.
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
JP2018512388A (ja) 二価ブタインフルエンザウイルスワクチン
Loy et al. Development and evaluation of a replicon particle vaccine expressing the E2 glycoprotein of bovine viral diarrhea virus (BVDV) in cattle
CO5611162A2 (es) Metodos para prevenir enfermedades reproductivas en el ganado vacuno
ES2355276T3 (es) Vacunas virales mutantes y seguras.
RU2010120324A (ru) Вакцина против вируса синего языка и иммуногенные композиции, способы их применения и способы их получения
RS52188B (sr) Pseća vakcina za zaštitu od erlihioze
UY40490A (es) Vacunas de combinación para prevenir y/o tratar múltiples agentes infecciosos
CO2023014970A2 (es) Vacuna contra el coronavirus que comprende una proteina mosaico
RU2021112503A (ru) Поливалентная вакцина против м. hyo и её применение
DK2569007T3 (en) VACCINE AGAINST Mycoplasma hyopneumoniae SUITABLE FOR ADMINISTRATION IN PRESENCE OF maternally derived antibodies
ES2643031T3 (es) Vacuna contra garrapatas de Rhipicephalus
AR040623A1 (es) Vacuna contra el virus de la aftosa.
ATE442857T1 (de) Vakzine zusammensetzung zur impfung von hunden gegen infektiöse atemwegserkrankung bei hunden (cird)
Camussone et al. Immune response and functional role of antibodies raised in heifers against a Staphylococcus aureus CP5 lysate and recombinant antigens vaccine formulated with Iscom Matrix adjuvant

Legal Events

Date Code Title Description
FD Application declared void or lapsed